DNLI

Denali Therapeutics Inc. (NASDAQ:DNLI) is a biopharmaceutical company founded in 2013 and headquartered in South San Francisco, California. Originally incorporated as SPR Pharma Inc., the company changed its name to Denali Therapeutics in March 2015 and went public in December 2017. Denali focuses exclusively on discovering and developing therapeutic candidates for neurodegenerative diseases, a challenging area of medicine where few effective treatments currently exist. The company operates as a clinical-stage biotech firm with multiple drug candidates in various phases of development, targeting conditions such as Parkinson's disease, ALS (amyotrophic lateral sclerosis), Huntington's disease, and other neurological disorders.